Analyst consensus rating
Enanta Pharmaceuticals Analyst Rating: none
Direct answer
Enanta Pharmaceuticals's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.83.
Forecast evidence checked November 14, 2026.
Get free Enanta Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.99
- Average price target
- $21.83
- High price target
- $32.00
- Low price target
- $19.00
- Low target gap
- +72.9%
- Target upside
- +98.7%
- High target gap
- +191.2%
- Target range width
- 118.3%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $21.83.
How far are Enanta Pharmaceuticals's low and high targets from the recorded price?
The low target implies +72.9%, while the high target implies +191.2%.
How many analysts are included in Enanta Pharmaceuticals's consensus?
The verified consensus includes 6 analysts.
How is Enanta Pharmaceuticals's target upside or downside calculated?
The average target of $21.83 is divided by the recorded price of $10.99, then one is subtracted to produce +98.7%. This does not guarantee a future return.
When was Enanta Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.